Der er i placebokontrollerede undersøgelser med hypertensive patienter ikke set nogen forskel i den samlede bivirkningshyppighed i irbesartan/ hydrochlorthiazidgrupperne og placebogrupperne.
In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan/ hydrochlorothiazide and the placebo groups.